Early On-treatment Changes in Circulating Tumor DNA Fraction and Response to Enzalutamide or Abiraterone in Metastatic Castration-Resistant Prostate Cancer - Concepedia

Concepedia

Publication | Open Access

Early On-treatment Changes in Circulating Tumor DNA Fraction and Response to Enzalutamide or Abiraterone in Metastatic Castration-Resistant Prostate Cancer

DOI Full Paper Access

50

Citations

41

References

2023

Year

Sofie H. Tolmeijer, Emmy Boerrigter, Takayuki Sumiyoshi, Edmond M. Kwan, Sarah W.S. Ng, Matti Annala, Gráinne Donnellan, Cameron Herberts, Guillemette E. Benoist, Paul Hamberg,

Clinical Cancer Research

Abstract

Early changes in ctDNA fraction are strongly linked to duration of first-line ARPI treatment benefit and survival in mCRPC and may inform early therapy switches or treatment intensification. See related commentary by Sartor, p. 2745.

References

	Year	Citations

Page 1